Lineage Cell Therapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 04/19/2024
Lineage Cell Therapeutics Stock Forecast and Price Target
If Lineage Cell Therapeutics's stock price reached the average yearlong target of $5.00 given by well-known analysts in recent months, there would be a potential upside of approximately 316.67% from its last closing price in April, 2024. This potential increase is based on a high estimate of $7.00 and a low estimate of $4.00. Although you may not be interested in LCTX stock, you should still be aware of its competitors.
316.67% Upside
Lineage Cell Therapeutics Fair Value Forecast for 2023 - 2025 - 2030
Lineage Cell Therapeutics's Price has grown in the last two years, jumping from $0.00 to $0.00 – an increase of 100.00%. In the next year, analysts predict that Fair Value will reach $1.29 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MRK Stock Forecast | Merck | Outperform |
2
|
$125.23 | Buy/Sell | $130.51 | 11.00% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$105.27 | Buy/Sell | $118.92 | 20.64% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$25.39 | Buy/Sell | $32.87 | 20.13% |
| SAN Stock Forecast | Sanofi | Outperform |
16
|
85.23€ | Buy/Sell | 102.80€ | 26.72% |
| MDT Stock Forecast | Medtronic | Outperform |
11
|
$79.19 | Buy/Sell | $92.47 | 20.60% |
Lineage Cell Therapeutics Revenue Forecast for 2023 - 2025 - 2030
Lineage Cell Therapeutics's Revenue has grown in the last three years, jumping from $1.83M to $8.95M – an increase of 389.07%. In the next year, analysts predict that Revenue will reach $18.48M – an increase of 106.48%. For the next seven years, the forecast is for Revenue to grow by 3598.99%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GSK Stock Forecast | GSK | Outperform |
12
|
£15.84 | Buy/Sell | £17.30 | 23.11% |
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$39.65 | Buy/Sell | $44.86 | 13.49% |
| TEVA Stock Forecast | Teva Pharmaceutical Industries | Outperform |
12
|
$12.78 | Buy/Sell | $11.59 | 25.20% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MDXG Stock Forecast | MiMedx Group | Buy |
6
|
$6.16 | Buy/Sell | $11.85 | 94.81% |
| OFIX Stock Forecast | Orthofix Medical | Hold |
10
|
$13.02 | Buy/Sell | $18.00 | 15.21% |
| AXGN Stock Forecast | AxoGen | Buy |
6
|
$6.55 | Buy/Sell | $12.50 | 113.74% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CGEN Stock Forecast | Compugen | Buy |
7
|
$1.88 | Buy/Sell | $4.00 | 165.96% |
| MSB Stock Forecast | Mesoblast | Buy |
9
|
$0.78 | Buy/Sell | $0.69 | 41.03% |
| XTNT Stock Forecast | Xtant Medical Holdings | Buy |
0
|
$0.84 | Buy/Sell | $1.93 | 129.76% |
Lineage Cell Therapeutics EBITDA Forecast for 2023 - 2025 - 2030
Lineage Cell Therapeutics's EBITDA has increased by 1.39% In the last three years, going from $-23.71M to $-24.04M. In the next year, analysts expect EBITDA to reach $-27.33M – an increase of 13.69%. By 2030, professionals believe that Lineage Cell Therapeutics's EBITDA will decrease by 181.24%, reaching $19.53M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PLUR Stock Forecast | Pluri | - |
9
|
$5.05 | Buy/Sell | $4.00 | -100.00% |
| ACOR Stock Forecast | Acorda Therapeutics | - |
5
|
$0.43 | Buy/Sell | $200.00 | -100.00% |
| BRTX Stock Forecast | BioRestorative Therapies | Outperform |
0
|
$1.44 | Buy/Sell | $15.00 | 629.17% |
Lineage Cell Therapeutics EBIT Forecast for 2023 - 2025 - 2030
Lineage Cell Therapeutics's EBIT has decreased In the last three years, from $-25.75M to $-24.73M – a 3.96% drop. In the following year, 6 experts forecast Lineage Cell Therapeutics's EBIT will decrease by 3.80%, to $-23.79M. In 2030, professionals predict that Lineage Cell Therapeutics's EBIT will decrease by 1069.47%, to $239.75M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| RENE Stock Forecast | ReNeuron Group |
7
|
£0.03 | Buy/Sell | £0.55 | 1733.33% | |
| ATHX Stock Forecast | Athersys | - |
6
|
$0.00 | Buy/Sell | $5.50 | 0.00% |
| ISCO Stock Forecast | International Stem Cell | - |
4
|
$0.07 | Buy/Sell | $37.50 | -100.00% |
Lineage Cell Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
Lineage Cell Therapeutics's EPS has grown in the last two years, jumping from $-0.14 to $0.00 – an increase of 100.00%. In the next year, analysts predict that EPS will reach $-0.11 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PRED Stock Forecast | Predictive Technology Group | - |
0
|
$0.00 | Buy/Sell | $7.00 | 0.00% |
| CRYO Stock Forecast | American CryoStem | - |
0
|
$0.00 | Buy/Sell | $0.00 | 0.00% |
| 542765 Stock Forecast | Transpact Enterprises | - |
0
|
380.00 | Buy/Sell | 0.00 | -100.00% |
Site Navigation
.jpg)